Efeitos adversos durante a infusão de infliximabe em crianças e adolescentes: estudo multicêntrico

• Autor(a) principal: Barbosa, Cassia Maria Passarelli Lupoli [UNIFESP]
• Data de Publicação: 2008
• Outros Autores: Terreri, Maria Teresa Ramos Ascensão [UNIFESP], Oliveira, Sheila K. F., Rodrigues, Marta Cristine Felix, Bica, Blanca Elena Rios Gomes, Sacchetti, Silvana, Romanelli, Paulo Roberto Stocco, Len, Claudio Arnaldo [UNIFESP], Hilário, Maria Odete Esteves [UNIFESP]
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S0482-50042008000500005; http://repositorio.unifesp.br/handle/11600/4562
• topic: anti-TNF; adverse reactions; infusion reactions; infliximab; Children; anti-TNF; efeitos adversos; reações infusionais; infliximabe; Crianças

OBJECTIVE: To evaluate the frequency and the severity of the adverse reactions during the infusion of infliximab. METHODS: We performed a retrospective chart review of 58 patients, followed up at 5 paediatric rheumatology centers. All patients presented refractory disease or were intolerant to one or more disease modifying drugs and received one or more infliximab infusions. The data analysis was descriptive, considering the frequency and the kind of adverse reactions as well as the number of the infusions, the infliximab dose and the indication. RESULTS: The mean age at the onset of infliximab was 12 years and 9 months and the mean of the disease duration was 7 years and 7 months. The main indication of the drug was juvenile idiopathic arthritis (43). Twenty five out of 58 patients (43.1%) presented adverse reactions during the infusion and 17 (29,3%) had to withdraw the treatment. The reactions were: dyspnea (ten), nausea and vomiting (eight), rash (seven), anaphylaxis (six), flush (five), angioedema (four), chest pain (four) besides urticaria, hypertension, among others. The anaphylaxis was more frequent between the fourth and the sixth infusion. CONCLUSION: The frequency and the severity of adverse reactions to infliximab must be considered not only in relation to its indication, but mainly for the choice of the center to the drug infusion where emergency treatment may be performed.